J&J CNS Studies Show Awareness Of CER And Broader Databases
Executive Summary
J&J's proposal to make long-acting anti-psychotic drugs a priority for the nation's push into comparative effectiveness research didn't make it onto the Institute of Medicine's "hot list" of research priorities released June 30 (1"The Pink Sheet" DAILY, June 30, 2009)
You may also be interested in...
Long-Acting Atypical Antipsychotic Market Snapshot: A One-Company Market Begins To Diversify
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.
J&J Pushes New Treatment Paradigm for Invega Sustenna
Johnson & Johnson is looking at innovative ways to build the value of its just-approved, monthly injectable schizophrenia drug Invega Sustenna, including continuing ongoing outcomes studies and creating appropriate partnerships with payers and others, as part of a broader plan for a "new treatment paradigm" in the treatment of schizophrenia
J&J Pushes New Treatment Paradigm for Invega Sustenna
Johnson & Johnson is looking at innovative ways to build the value of its just-approved, monthly injectable schizophrenia drug Invega Sustenna, including continuing ongoing outcomes studies and creating appropriate partnerships with payers and others, as part of a broader plan for a "new treatment paradigm" in the treatment of schizophrenia